YARW logo

YARROW BIOSCIENCE INC

YARWNASDAQ
🏆 #3643 by market capEarnings Nov 4US Equity
$19.20▼ $0.37 (−1.90%)
Latest quote
🔔
Track YARW
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.9%
7d▼ 1.7%
14d▼ 3.0%
30d▼ 20.3%
ytd▼ 33.8%
1y▲ 12.1%
🏦Market Cap
$181M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
371.5x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$19.12 – $19.79
52-Week Range
$18.05 – $44.28
Volume (shares)
69,956.354
Avg Volume (shares)
—
Shares Outstanding
9.4M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$570,000
Last Q Revenue
$97,000
P/E Ratio
—
P/S Ratio
371.5x
EPS (TTM)
$-21.85
Dividend Yield
—
Dilution (1yr)
−21.8%
YARW logo

YARROW BIOSCIENCE INC

YARW
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$570K▲ +13.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.0%▼ −4.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$30M▼ −31.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −2.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
666K▼ −21.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24M▲ +$4M YoY
StockOtter · stockotter.space

About YARROW BIOSCIENCE INC

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

Defense World·Sep 21

Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)

Yarrow Bioscience (NASDAQ: YARW - Get Free Report) and Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two busines

Business Wire·Sep 14

Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases

Business Wire·Sep 10

Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases

Business Wire·Sep 10

Yarrow Bioscience Announces Proposed Underwritten Public Offering

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases

Business Wire·Aug 13

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.